News & Updates

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024 bySarah Cheung

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

 

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
Are heat-related illnesses in SG a cause for alarm?
Are heat-related illnesses in SG a cause for alarm?
05 Mar 2024
Glaucoma tied to increased risk of Alzheimer's, related dementias
Glaucoma tied to increased risk of Alzheimer's, related dementias
01 Mar 2024

Individuals with glaucoma, particular those diagnosed at older ages, are prone to developing Alzheimer’s disease (AD), vascular dementia (VaD), and all-cause dementia (ACD), reports a study.

Glaucoma tied to increased risk of Alzheimer's, related dementias
01 Mar 2024